Pricing Policy and the Modality Map: How U.S. Drug Pricing Reform Reprices Therapeutic Areas and Technology Platforms

Background. United States pharmaceutical pricing policy does not act uniformly across the drug development pipeline. The 2022 Inflation Reduction Act exposes small-molecule drugs to Medicare price negotiation nine years after approval. However, it protects biologics for thirteen years, and the 2025 Most-Favored-Nation executive order ties United States prices to the lowest price paid by comparable wealthy nations. This study examines how these two policies reprice therapeutic areas and technology platforms, and how that repricing feeds back into early-stage investment. Methods. This mixed-methods review combines a structured synthesis of peer and non-peer review publications, a discounted-cash-flow-transmission argument, and a therapeutic-area exposure-scoring framework, with every cited claim checked for a verifiable source. The analysis evaluated the six therapeutic areas and four platform classes on multiple factors, including international price differential, Medicare-population concentration, negotiation timeline, and orphan-exemption eligibility. Results. Early-stage venture investment in small-molecule assets fell by roughly 68% after the 2022 law, leaving large-molecule investment about ten times larger by 2024, and post-approval oncology trials declined more for small molecules than biologics. Price exposure varies sharply by therapeutic area: United States prices run about 4.8 times higher for cardiovascular drugs but only 1.1 to 1.2 times higher for orphan and cell-and-gene treatments. Cardiovascular, metabolic, immunologic, and Medicare-aged neurological assets face the highest combined exposure; orphan and cell-and-gene assets face the lowest. A 30% cut to projected peak revenue more than halves a preclinical asset's present value once staged probabilities and discounting compound. Conclusions. Together with broader price deflation, these two policies represent the most significant repricing of risk-adjusted pharmaceutical research and development returns in a generation, and capital is already shifting toward biologics, orphan indications, and cell-and-gene therapies.